Because SPINK1 partially exhibits its neoplastic effects through its interaction with EGFR, EGFR inhibitors may be a potential targeted therapy for SPINK1-overexpressing prostatic cancers [119]. The gene discussed is SPINK1; the disease is prostate cancer.